Sweet Victory: Eli Lilly's Jardiance Is First Diabetes Drug To Reduce Heart Attacks And Strokes

A big win for Eli Lilly this morning. Its diabetes drug Jardiance, co-marketed with Boehringer Ingelheim,  is the first blood-sugar lowering pill ever to reduce the risk of heart attacks, strokes, and cardiovascular deaths in a big study, according to a press release issued this morning.
Source: Forbes.com Healthcare News - Category: Pharmaceuticals Authors: Source Type: news

Related Links:

ConclusionClopidogrel monotherapy was neither inferior nor superior to aspirin monotherapy for the secondary prevention of recurrent cerebrovascular attack following previous ischemic stroke in patients with T2DM. Hence, clopidogrel or aspirin monotherapy is equally safe and effective in these patients with T2DM.
Source: Diabetes Therapy - Category: Endocrinology Source Type: research
Authors: Aung AT, Chan SP, Kyaing TT, Lee CH Abstract Introduction: Compared to clinic blood pressure (BP), sleep-time BP and non-dipping BP pattern are better predictors of target organ damage and cardiovascular sequalae.Aim: In a retrospective study, we determined whether diabetes mellitus (DM) status is associated with high sleep-time BP and non-dipping pattern.Methods: We analyzed 1092 patients who underwent ambulatory BP monitoring between 2015 and 2017 in a tertiary cardiology institution. During a 24-hour period, BP was automatically measured every 15 minutes between 7:00 AM and 11:59 PM and every 30&nb...
Source: Postgraduate Medicine - Category: Internal Medicine Tags: Postgrad Med Source Type: research
When Dr. Mark Lewis has to tell a cancer patient they’re dying, he tries to do so as compassionately as possible, usually offering a hug or a hand to hold. The thought of doing so by phone, he says, once felt heartbreakingly impersonal. But in the face of the current COVID-19 pandemic, the Salt Lake City-based gastrointestinal oncologist has had to do many things that make his “conscience weigh heavy.” He’s delivered bad news virtually, to limit the possibility of spreading the virus. He’s delayed chemotherapy for patients who—he hopes—can wait, knowing the treatment would wipe out...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized COVID-19 Magazine Source Type: news
(CNN) — Ending your day with a hot bath might have more benefits than just relaxation. It could also lower your risk of heart disease and stroke, a new study finds. Previous research on bathing has already shown that it’s beneficial for sleep quality and how healthy a person thinks they are. A new study, published Tuesday in the journal Heart, found that a daily hot bath is also associated with a 28% lower risk of heart disease, and a 26% lower risk of stroke — likely because taking a bath is also associated with lowering your blood pressure, the researchers said. They discovered this after tracking the b...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - Category: Consumer Health News Authors: Tags: Health News Syndicated CBSN Boston CNN Source Type: news
This study included 1962 patients who underwent transesophageal echocardiographic examination (TEE) prior to cardioversion or ablation in the years 2014-2018 in three cardiac centers. RESULTS: More than a quarter of AF patients had decreased eGFR (
Source: Cardiology Journal - Category: Cardiology Authors: Tags: Cardiol J Source Type: research
Higher intake of isoflavones and tofu associated with moderately lower risk of developing CHD especially for some women Related items fromOnMedica Taxing unhealthy products may help tackle chronic diseases Most supplements offer no real benefit, some might increase risks Plant-based diet linked to lower risk of heart failure Vitamin D supplements do not confer cardiovascular protection Fish oils do not prevent heart attack or strokes with diabetes
Source: OnMedica Latest News - Category: UK Health Source Type: news
Conclusions: Preliminary literature suggests that FMT may be a promising treatment option for several neurological disorders. However, available evidence is still scanty and some contrasting results were observed. A limited number of studies in humans have been performed or are ongoing, while for some disorders only animal experiments have been conducted. Large double-blinded randomized controlled trials are needed to further elucidate the effect of FMT in neurological disorders.
Source: Frontiers in cellular and infection microbiology - Category: Microbiology Source Type: research
AbstractBackgroundOral Factor Xa inhibitors for the prevention of stroke in atrial fibrillation require dose adjustment based on certain clinical criteria, but the off-label use of the reduced doses is common.MethodsData from an observational registry including patients admitted with acute cerebral ischemia while taking oral Factor Xa inhibitors for atrial fibrillation between April 2016 and December 2018 were investigated. The dose regimen of the Xa inhibitor was classified as “appropriate”, “underdosed” and “overdosed” in conformity with the European Medicines Agency labelling. The eff...
Source: Journal of Neurology - Category: Neurology Source Type: research
z MGR Abstract BACKGROUND: Interleukin-18 (IL-18), a proinflammatory and proatherogenic cytokine, has been associated with type 2 diabetes, metabolic syndrome, stroke and coronary artery disease. Some studies have indicated that the IL-18 promoter -137 G/C polymorphism seems to be associated with changes in the IL-18 expression and may contribute to the development of cardiovascular disease (CVD). The aim of this study was to evaluate the association between -137 G/C polymorphism and the levels of IL-18, biochemical markers for cardiovascular disorders, anthropometric profile and cardiovascular disease in Brazilia...
Source: Clinical Biochemistry - Category: Biochemistry Authors: Tags: Clin Biochem Source Type: research
RARITAN, N.J., March 20, 2020 – The Janssen Pharmaceutical Companies of Johnson &Johnson announced today that it will unveil late-breaking data from its leading cardiovascular and metabolism portfolio during the virtual American College of Cardiology’s 69th Annual Scientific Session together with the World Congress of Cardiology (ACC.20/WCC) on March 28-30, 2020. Notably, four late-breaking abstracts for XARELTO® (rivaroxaban) will be presented, including data from the Phase 3 VOYAGER PAD study in patients with symptomatic peripheral artery disease (PAD) after lower-extremity revascularization.Click to ...
Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news
More News: Cardiology | Cardiovascular | Diabetes | Empagliflozin | Endocrinology | Heart | Jardiance | Pharmaceuticals | Stroke | Study